Psychedelics panel invited to mainstream healthcare conference

After many years of dormancy, research and public interest in psychedelics has expanded. Once-obscure topics, such as ayahuasca, now receive major media coverage in stories claiming psychological benefits, and the public routinely hears about MDMA and other substances… The need for training of mental health professionals in various competency areas related to psychedelics is increasingly apparent. Dialogue between psychedelics researchers and mental health clinicians is more important than ever. Although mental health clinicians and healthcare researchers have a lot to learn about this topic, these same professionals also have a lot to contribute in this dynamic cultural/scientific landscape.

This exposure creates a need for psychologists to respond with scientifically and multiculturally informed perspectives, to bring expertise to the discussion. Psychedelic substances have been combined with psychotherapy to form unique, multimodal interventions for mental health problems. Recent randomized controlled trials have provided evidence for the utility of MDMA and psilocybin as adjuncts to psychotherapy. MDMA is in the third and final phase of clinical trials to become part of an FDA-approved treatment for PTSD. Granted “breakthrough status,” it might soon be available to more patients as a combined psychotherapeutic/psychopharmacologic intervention. Psychologists have the opportunity to help navigate new clinical, ethical, and cultural issues in current expansions of research in psychedelic-assisted psychotherapy, and develop competence in related practices.

From the Article (Chacruna):
Psychedelics Panel Invited to Mainstream Healthcare Conference
Artwork Fair Use: Drugs Lab


Home grow…


…for macrodosing

Leave a Reply